




PHARMACEUTICAL 2021

Eterna Therapeutics Inc.
Rank 330 of 402





RealRate

PHARMACEUTICAL 2021

Eterna Therapeutics Inc. Rank 330 of 402



The relative strengths and weaknesses of Eterna Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eterna Therapeutics Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 121% points. The greatest weakness of Eterna Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 232% points.

The company's Economic Capital Ratio, given in the ranking table, is -89%, being 137% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	1,724
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,360
Liabilities, Non-Current	532
Other Assets	1,519
Other Compr. Net Income	-23
Other Expenses	4,012
Other Liabilities	2.0
Other Net Income	1,888
Other Revenues	5,800
Property and Equipment	502
Research and Development	0
Selling, General and Administrative Expense	8,091

Output Variable	Value in 1000 USD
Assets	3,745
Liabilities	2,894
Expenses	12,103
Revenues	5,800
Stockholders Equity	851
Net Income	-4,415
Comprehensive Net Income	-4,426
Economic Capital Ratio	-89%